When your CRO uses AI on your trial, you remain accountable for the results. Regulators will not accept "the vendor's algorithm did it" as an explanation for a missed safety signal or a flawed dataset. Sponsor oversight has to extend to the tools your vendors use, not just the people.
This is a quiet shift that many emerging sponsors have not noticed yet. CROs are embedding machine learning into monitoring, data cleaning, medical coding, safety intake and document management. Much of it is genuinely useful. Very little of it is visible in the proposal or the contract.
Why AI changes the oversight equation
Traditional oversight assumes a human performed the task and a human can explain it. You review the monitoring report, you question the CRA, you audit the process. AI introduces a layer where the reasoning may be opaque, the model may change over time, and the vendor's own staff may not fully understand how an output was generated.
ICH E6(R3) is clear that sponsors retain ultimate responsibility for trial conduct and data integrity, and that oversight should be proportionate to risk. An AI tool that flags which sites need an on-site visit carries real risk. If it under-flags, your monitoring strategy has a hole in it that you may not see until inspection.
What should sponsors ask their CRO about AI?
Build these questions into your oversight plan and your governance meetings:
Which study activities use AI or machine learning, and at what step?
Is the output reviewed by a qualified person before it drives a decision?
How was the tool validated, and against what intended use?
How are model updates controlled, and will you be notified?
Who owns the data used to train or tune the model, and does it include your study data?
What audit trail exists for AI-assisted decisions?
If your CRO cannot answer these clearly, that is itself a finding. It does not mean the tool is bad. It means the governance around it is immature.
Put it in the oversight plan, not just the contract
Contracts matter, but oversight happens in the operating rhythm. Add AI-assisted activities to your vendor oversight plan with the same specificity you give to monitoring visits. Define which outputs you will sample, how often, and what triggers escalation. Ask for periodic performance data on the tool itself: false positive rates for risk signals, accuracy of auto-coded terms, rework rates on AI-classified TMF documents.
For small sponsors with limited internal staff, this can feel like a lot. It is less burdensome than it sounds if you focus on the tools that influence patient safety and data integrity, and apply lighter touch to administrative automation.
The inspection lens
Imagine an inspector asks how you knew your CRO's risk-based monitoring algorithm was working. A strong answer shows the oversight plan, the periodic review, the sample checks and the documented escalation. A weak answer is a slide from the vendor's sales deck.
The principle has not changed. You can delegate tasks to a CRO. You cannot delegate accountability. AI simply raises the stakes on knowing exactly what you delegated.
